?Protein Technology Shared Resource The goal of the Protein Technology Shared Resource (PTSR) is to generate protein reagents and provide analytical instrumentation that enables SJCCC members to explore the biology and therapeutic consequences of altered protein function in cancer. The PTSR offers state-of-the-art technologies for protein expression and purification from bacteria, insect cells, and mammalian host systems, and provides expert consultation to SJCCC members regarding their needs for these services. The core has recently upgraded its protein expression pipeline by acquiring contemporary automated protein purification systems to enhance the quality of the final product and the documentation of its purity. The PTSR was founded and has been directed by Charles Rock, PhD, an expert in protein expression and purification. Moving forward, the leadership of the PTSR is transitioning in the next funding period to Charalampos Kalodimos, PhD (CBP), the new Chair of the Department of Structural Biology. Kalodimos has decades of experience in protein biochemistry and brings new energy and vision to enhancing the impact of the PTSR on SJCCC research. Currently, Rock and Kalodimos are co- directing the PTSR for one year to ensure a smooth transition in leadership. When new components are fully integrated into the PTSR, the resource will have 9 technical staff, 1 manager, and the Director (Kalodimos). The PTSR is a highly specialized Shared Resource that provides a relatively small but crucial service with a significant impact on the science of the SJCCC. The centralization of resources for protein production, purification, and analysis provides economic value to SJCCC members, and the PTSR can usually offer substantial savings even for commercially available proteins. Cytokines, for example, cost $10 to $30 per microgram commercially, whereas PTSR recently produced 250 micrograms of M-CSF for Kanneganti (CBP) for $0.50 per microgram, saving hundreds of thousands of dollars. Of the 26 manuscripts using the PTSR, 7 (27%) involved intraprogrammatic collaboration, and 4 (15%) involved interprogrammatic collaboration. Work involving the PTSR has had marked scientific impact, including publications from 4 of the 5 Programs, CBP (n=20), DBSTP (n=7), HMP (n=3), and NBTP (n=1). In the upcoming funding period, the PTSR will continue to offer bacterial, insect, and mammalian cell expression systems for protein production, supported by existing fermentation equipment and cell culture facilities. The transition in Directors will be completed, and services will be significantly expanded and improved, including expansion of the protein-expression capabilities and the integration of the molecular-interaction components. State-of-the art cloning and expression services will be augmented by the addition of a Hudson Robotics ProLink Protein Expression System capable of performing high-throughput expression screens of multiple clones, which will be operational by July 2018.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA021765-41
Application #
9883745
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-03-01
Budget End
2021-02-28
Support Year
41
Fiscal Year
2020
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Scott, Jessica M; Li, Nan; Liu, Qi et al. (2018) Association of Exercise With Mortality in Adult Survivors of Childhood Cancer. JAMA Oncol 4:1352-1358
Rong, Yongqi; Bansal, Parmil K; Wei, Peng et al. (2018) Glycosylation of Cblns attenuates their receptor binding. Brain Res 1694:129-139
Levine, Jennifer M; Whitton, John A; Ginsberg, Jill P et al. (2018) Nonsurgical premature menopause and reproductive implications in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer 124:1044-1052
Li, Jian-Feng; Dai, Yu-Ting; Lilljebjörn, Henrik et al. (2018) Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proc Natl Acad Sci U S A 115:E11711-E11720
Sharma, Akshay; Kang, Guolian; Sunkara, Anusha et al. (2018) Haploidentical Donor Transplantation Using a Novel Clofarabine-containing Conditioning Regimen for Very High-risk Hematologic Malignant Neoplasms. J Pediatr Hematol Oncol 40:e479-e485
Waszak, Sebastian M; Northcott, Paul A; Buchhalter, Ivo et al. (2018) Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol 19:785-798
Zheng, Wenting; O'Hear, Carol E; Alli, Rajshekhar et al. (2018) PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells. Leukemia 32:1157-1167
Heikamp, Emily B; Pui, Ching-Hon (2018) Next-Generation Evaluation and Treatment of Pediatric Acute Lymphoblastic Leukemia. J Pediatr 203:14-24.e2
Sadighi, Zsila S; Curtis, Elizabeth; Zabrowksi, Jennifer et al. (2018) Neurologic impairments from pediatric low-grade glioma by tumor location and timing of diagnosis. Pediatr Blood Cancer 65:e27063
Wierdl, Monika; Tsurkan, Lyudmila; Chi, Liying et al. (2018) Targeting ALK in pediatric RMS does not induce antitumor activity in vivo. Cancer Chemother Pharmacol 82:251-263

Showing the most recent 10 out of 6764 publications